Advertisement
Prior to joining Interleukin Genetics, Mr. Walker was the Worldwide Marketing Director for the Biopatch and OMNEX and synthetic sealants for Johnson & Johnson (JNJ) having worked in the Ethicon Inc., Jansen, Ortho-McNeil and PSGA divisions. Mr. Walker was responsible for developing global marketing strategies, establishing and influencing regional launches for products and building the framework for multigenerational product plans. Prior to joining Johnson & Johnson, Mr. Walker worked as a manager in various capacities with the Procter & Gamble Company.
Advertisement
"We are very pleased to have Todd Walker join Interleukin Genetics as Vice President, Marketing. He brings extensive experience in marketing of pharmaceutical and medical products to the consumer. Todd will have an office in Ada, Michigan, as well as Waltham Massachusetts, and he will spend significant time at our primary customer, Alticor," said Lewis H. Bender Chief Executive Officer at Interleukin Genetics.
Mr. Walker holds a Masters of Business Administration from Duke University's FUQUA School of Business, and a Bachelor's of Science Electrical Engineering Degree from Union College in Schenectady, New York.
About Interleukin Genetics
Interleukin Genetics, Inc. (Amex: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.
Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
SOURCE Interleukin Genetics, Inc.
